Clinical Trial Update: Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating osimertinib in combination with bevacizumab for EGFR exon 20 insertion metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Osimertinib (osimertinib)

Snippet

Sponsor: Qingdao Central Hospital | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN